MetLife’s higher investment income supporting results, says Argus

Argus keeps a Buy rating and $90 price target on MetLife (MET), noting that the firm has a positive view of the company’s business diversification, expansion through both M&A and organic growth, and its commitment to shareholder returns. The stock trades at 1.4-times book value, in line with the peer median, but as an industry leader, it merits a higher multiple, the analyst tells investors in a research note.